Oncology Research Editorial Offfce

Oncology Research, Vol.33, No.12, pp. 4159-4159, 2025, DOI:10.32604/or.2025.075992 - 27 November 2025

Abstract This article has no abstract. More >

Oncology Research Editorial Offfce

Oncology Research, Vol.33, No.12, pp. 4157-4157, 2025, DOI:10.32604/or.2025.075991 - 27 November 2025

Abstract This article has no abstract. More >

Oncology Research Editorial Offfce

Oncology Research, Vol.33, No.12, pp. 4155-4155, 2025, DOI:10.32604/or.2025.075990 - 27 November 2025

Abstract This article has no abstract. More >

Boxuan Han^1,2,#, Shaokun Liu^3,#, Ridhima Das³, Shiqian Liu⁴, Yang Zhang^1,2,*

Oncology Research, Vol.33, No.12, pp. 3633-3656, 2025, DOI:10.32604/or.2025.071296 - 27 November 2025

Abstract Organoid technology, characterized by high fidelity in mimicking the in vivo microenvironment, preservation of tumor heterogeneity, and capacity for high-throughput operations, has emerged as a critical tool in head and neck cancer research. To address clinical challenges in head and neck cancer management—including marked tumor heterogeneity, therapeutic resistance, and significant prognostic variability—this review focuses on four key translational applications of organoid technology: In mechanistic studies, organoid models provide a reliable platform for investigating tumorigenesis, progression, and drug resistance mechanisms. In personalized therapy, organoid-based drug sensitivity testing enables data-driven clinical decision-making. For biomarker discovery, organoids facilitate the More >

Rym Akrout¹, Ludovic Leloup², Khouloud Ayed¹, Fabrice Parat², Sami Zekri^3,4, Wassim Y. Almawi¹, Rahma Boughriba¹, Hanen Attia¹, Olfa Masmoudi-Kouki⁴, Hervé Kovacic^2,*, Asma Gati^1,*

Oncology Research, Vol.33, No.12, pp. 3887-3906, 2025, DOI:10.32604/or.2025.070729 - 27 November 2025

Abstract Objectives: Cisplatin (CDDP) therapy for glioblastoma (GBM) is linked with several limitations, which include poor penetration of the blood-brain barrier (BBB), systemic toxicity, and the development of drug resistance mechanisms implicating oxidative stress dysregulation and compromised apoptotic pathways. This study evaluates C-Phycocyanin (C-PC) as a potential adjuvant to enhance CDDP efficacy by modulating redox balance and apoptosis. Methods: GBM cells (U87 and U87-EGFRvIII) were treated with CDDP, C-PC, or their combination. Cell viability was assessed by MTT assay; apoptosis was evaluated by DAPI staining and Western blot analysis of cleaved Caspase-3 and poly (ADP-ribose) polymerase… More > Graphic Abstract

Jiunn-Wei Wang^1,2,3, Wen-Hung Hsu^2,3,4, Fang-Jung Yu^2,3, Fu-Chen Kuo⁵, Chung-Jung Liu^3,6, Chao-Hung Kuo^1,2,3, Jaw-Yuan Wang^7,8, Ming-Hong Lin^9,*, Deng-Chyang Wu^1,2,3,*

Oncology Research, Vol.33, No.12, pp. 3907-3922, 2025, DOI:10.32604/or.2025.070432 - 27 November 2025

Abstract Objectives: Colorectal adenomatous polyps frequently recur after removal and are precursors to colorectal cancer, highlighting the need for effective preventive strategies. This study evaluated the efficacy of probiotic Clostridium butyricum MIYAIRI 588 (CBM588) in preventing colorectal adenoma recurrence in high-risk patients. Methods: We conducted a randomized, single-blind, two-year crossover trial in patients with a history of adenomatous polyps. Participants received CBM588 in either the first or second year, with the alternate year as observation, and underwent annual surveillance colonoscopies. Outcomes (adenoma recurrence and polyp counts) were analyzed by intention-to-treat (ITT) and per-protocol (PP) approaches. Results: A total… More >

Rawabi S. Altuwayjiri, Ibtesam S. Almami^*

Oncology Research, Vol.33, No.12, pp. 3923-3943, 2025, DOI:10.32604/or.2025.070104 - 27 November 2025

Abstract Objective: Testicular germ cell tumors (TGCTs) represent the most common malignancy among young men aged 20–40 years. Transglutaminase 7 (TG7), encoded by TGM7, is a poorly characterized enzyme whose function in TGCT remains unknown. This study aimed to assess TG7 expression in clinical specimens and investigate its functional role in a testicular germ cell tumor cell line (NT2/D1). Methods: TG7 protein expression was evaluated in clinical testicular tissue samples via immunohistochemistry (IHC) and immunofluorescence (IF). Functional analysis was conducted in the NT2/D1 human testicular cancer cell line using Dicer-substrate small interfering RNAs (DsiRNAs) targeting TG7. Gene… More >

Chenglu Lu^1,#, Huiting Zhang^2,#, Ujjal K. Bhawal^3,4, Lei Wang¹, Jingwu Li¹, Pangzhou Chen^5,*, Lewei Zhu^6,*

Oncology Research, Vol.33, No.12, pp. 3657-3678, 2025, DOI:10.32604/or.2025.069703 - 27 November 2025

Abstract The tumor microenvironment (TME) is a complex network composed of non-tumor cells, extracellular matrix, blood vessels, and various molecular signals that surround and profoundly influence tumor progression. As one of the key immune effector cells within the TME, mast cells (MCs) exhibit functional complexity, and their specific roles remain widely debated. Depending on the cancer type, spatial distribution, and interactions with other TME components, MCs can demonstrate dual regulatory capabilities—either promoting or inhibiting tumor growth. This characteristic has made them an important focus in current tumor immunology research. This review aims to systematically review the More >

Muhammad Noman Khan^1,2,3,*, Kang Tian², John R. Gordon⁴, Fang Li², Song-Ze Ding^1,*

Oncology Research, Vol.33, No.12, pp. 3837-3854, 2025, DOI:10.32604/or.2025.069408 - 27 November 2025

Abstract Objectives: Chemotherapy-induced lung inflammation limits the efficacy of anticancer therapies such as gefitinib in non-small cell lung cancer (NSCLC). Glutamic acid-leucine-arginine positive (ELR+) CXC chemokines and their receptors, CXC chemokine receptor 1 and 2 (CXCR1 and CXCR2), mediate both inflammatory responses and tumor progression. This study evaluated the effects of CXCR1/2 antagonism by G31P, a CXC motif chemokine ligand 8 (CXCL8)-mutated peptide, alone or in combination with gefitinib, on lung cancer growth and chemotherapy-induced pulmonary inflammation. Methods: Human NSCLC cell lines (A549 and H460) were treated with gefitinib and/or G31P. Cell proliferation, apoptosis, and signaling… More > Graphic Abstract

Khanh Toan Nguyen^1,*, Thi Huong Pham^1,2, Van Lam Ngo¹, Thi Thuy My Nguyen¹, Thi Dao Nguyen¹, Khanh Hung Truong¹, Van Nhat Nguyen¹, Van Thanh Le¹, Ba Duc Ho¹, Thi Phuong Thao Nguyen¹, Thi Ha Phuong Nguyen¹, Thi My Linh Dinh¹, Thi Hong Anh Vo¹, Thi Thuy Phan¹, Thi Hai Yen Le¹, Thi Nhung Ngo¹, Khanh Ha Nguyen¹

Oncology Research, Vol.33, No.12, pp. 4013-4028, 2025, DOI:10.32604/or.2025.069281 - 27 November 2025

Abstract Objective: Patients with stage III non-small cell lung cancer (NSCLC) present with a heterogeneous disease profile and often require multifaceted treatment strategies. This research aimed to investigate the demographic features, therapeutic patterns, and survival outcomes of such patients in Vietnam. Methods: A retrospective descriptive study was conducted on 731 patients diagnosed with stage III NSCLC American Joint Committee on Cancer (AJCC) 8th edition, at Nghe An Oncology Hospital from January 2018 to August 2024. Descriptive statistics summarized baseline and treatment characteristics. We calculated progression-free survival (PFS) and overall survival (OS) through the Kaplan–Meier approach and… More >